Hangzhou Highlightll Pharmaceutical Co., Ltd
Clinical trials sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New arthritis drug TLL-018 moves to Long-Term safety check in 350 patients Results expected Dec 2026 (estimated)
- New eczema ointment shows promise in early trial Results expected Jun 2027 (estimated)
- Can a new pill tame rheumatoid arthritis when standard drugs fail? Results expected Jul 2027 (estimated)
-
Can a daily pill tame severe eczema?
Disease control Not yet recruitingThis clinical trial is testing an oral medication called TLL-018 in adults with moderate-to-severe atopic dermatitis, a chronic skin condition causing itchy, inflamed skin. The study aims to see if TLL-018 can significantly improve skin symptoms compared to a placebo. Participant…
Phase 2/3 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a new pill quiet stubborn chronic hives?
Disease control Not yet recruitingThis phase II trial tests whether an experimental oral drug called TLL-018 can reduce itching and hives in adults with moderate-to-severe chronic spontaneous urticaria (CSU) that hasn't responded to standard antihistamines. Participants will take either a low or high dose of TLL-…
Phase 2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Can a new pill tame rheumatoid arthritis when standard drugs fail?
Disease control Not yet recruitingThis trial is testing an experimental drug called TLL-018 in adults with moderate-to-severe rheumatoid arthritis who haven't responded well to or couldn't tolerate standard treatments. Participants will receive either TLL-018 or a placebo for a period, and the study will measure …
Phase 2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill aims to stop chronic hives fast when antihistamines fail
Symptom relief Not yet recruitingThis early-phase trial tests a new drug called TLL-018 in 36 adults with moderate-to-severe chronic spontaneous urticaria (hives) that standard antihistamines can't control. The goal is to see how quickly TLL-018 reduces itching and hives after the first dose. Participants will r…
Phase 1/2 • Sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd • Aim: Symptom relief
Last updated Aug 26, 2026 00:00 UTC